RARE: first_quarter 2026 lobbying report

{"url":"https://lda.gov/api/v1/filings/bac5f3b1-3daf-48cf-80cf-c3dd4ac96fac/","filing_uuid":"bac5f3b1-3daf-48cf-80cf-c3dd4ac96fac","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/bac5f3b1-3daf-48cf-80cf-c3dd4ac96fac/print/","filing_document_content_type":"text/html","income":"40000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Alisa Hess","dt_posted":"2026-07-20T16:06:51-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"500 North Capitol Street, NW","registrant_address_2":"Suite 210","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":1171,"url":"https://lda.gov/api/v1/registrants/1171/","house_registrant_id":31749,"name":"ALPINE GROUP PARTNERS, LLC.","description":"Public relations consulting firm","address_1":"500 North Capitol Street, NW","address_2":"Suite 210","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ALISA JANE HESS","contact_telephone":"+1 434-933-2535","dt_updated":"2026-08-19T14:46:16.762025-04:00"},"client":{"id":73945,"url":"https://lda.gov/api/v1/clients/73945/","client_id":73945,"name":"ULTRAGENYX PHARMACEUTICAL INC.","general_description":"Biopharma company developing treatments for rare and ultra-rare diseases.","client_government_entity":null,"client_self_select":false,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2026-02-03"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Monitoring FDA user fee regulation, including priority review voucher reauthorization; legislation around screening efforts for newborns and ultra-rare diseases likeDuchenne Muscular Dystrophy (DMD) and Metachromatic Leukodystrophy (MLD)","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":145638,"prefix":null,"prefix_display":null,"first_name":"SHAYNE","nickname":null,"middle_name":null,"last_name":"WOODS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":93714,"prefix":null,"prefix_display":null,"first_name":"KEENAN","nickname":null,"middle_name":null,"last_name":"AUSTIN REED","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":150052,"prefix":null,"prefix_display":null,"first_name":"ERIN","nickname":null,"middle_name":null,"last_name":"MENDELSOHN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"GOV","general_issue_code_display":"Government Issues","description":"Monitoring FDA user fee regulation, including priority review voucher reauthorization; legislation around screening efforts for newborns and ultra-rare diseases likeDuchenne Muscular Dystrophy (DMD) and Metachromatic Leukodystrophy (MLD)","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":145638,"prefix":null,"prefix_display":null,"first_name":"SHAYNE","nickname":null,"middle_name":null,"last_name":"WOODS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":93714,"prefix":null,"prefix_display":null,"first_name":"KEENAN","nickname":null,"middle_name":null,"last_name":"AUSTIN REED","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":150052,"prefix":null,"prefix_display":null,"first_name":"ERIN","nickname":null,"middle_name":null,"last_name":"MENDELSOHN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"Monitoring FDA user fee regulation, including priority review voucher reauthorization; legislation around screening efforts for newborns and ultra-rare diseases likeDuchenne Muscular Dystrophy (DMD) and Metachromatic Leukodystrophy (MLD)","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":145638,"prefix":null,"prefix_display":null,"first_name":"SHAYNE","nickname":null,"middle_name":null,"last_name":"WOODS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":93714,"prefix":null,"prefix_display":null,"first_name":"KEENAN","nickname":null,"middle_name":null,"last_name":"AUSTIN REED","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":150052,"prefix":null,"prefix_display":null,"first_name":"ERIN","nickname":null,"middle_name":null,"last_name":"MENDELSOHN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}